Abstract
Purpose
Molecular mechanisms of response to hypomethylating agents in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) still remain largely unknown. Therefore, the effects of 5-Azacytidine (Aza) on clonal architecture and DNA methylation were investigated in this study.
Methods
Using next-generation sequencing (NGS), 30 myeloid leukemia-associated genes were analyzed in 15 MDS/CMML patients with excellent response to Aza. Effects on methylation levels were analyzed by quantitative methylation analysis using pyrosequencing for the global methylation marker LINE-1 in patients and myeloid cell lines. Various myeloid cell lines and a healthy cohort were screened for methylation levels in 23 genes. Selected targets were verified on the MDS/CMML cohort.
Results
The study presented here showed a stable variant allele frequency and stable global methylation levels in responding patients. A significant demethylation of EZH2 and NOTCH1 was revealed in patients with Aza response.
Conclusions
A response to Aza is not associated with eradication of malignant clones, but rather with a stabilization of the clonal architecture. We suggest changes in CpG methylation levels of EZH2 and NOTCH1 as potential targets of epigenetic response to Aza treatment which may also serve as useful biomarkers after clinical evaluation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ades L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R et al (2013) Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 37(6):609–613
Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M, Agodi A (2014) LINE-1 hypomethylation in blood and tissue samples as an epigenetic marker for cancer risk: a systematic review and meta-analysis. PLoS One 9(10):e109478
Bollati V, Baccarelli A, Hou L, Bonzini M, Fustinoni S, Cavallo D et al (2007) Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res 67(3):876–880
Calo E, Wysocka J (2013) Modification of enhancer chromatin: what, how, and why? Mol Cell 49(5):825–837
Chang CW, Lu TP, She CX, Feng YC, Hsiao CK (2016) Gene-set analysis with CGI information for differential DNA methylation profiling. Sci Rep 19(6):24666
Deaton AM, Bird A (2011) CpG islands and the regulation of transcription. Genes Dev 25(10):1010–1022
Fenaux P, Ades L (2009) Review of azacitidine trials in intermediate-2- and high-risk myelodysplastic syndromes. Leuk Res 33(Suppl 2):S7–11
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562–569
European Medicines Agency (2018) EMA/450923/2016 – Vidaza, Annex I, summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/vidaza
Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N et al (2010) A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5(2):e9001
Illingworth RS, Bird AP (2009) CpG islands–‘a rough guide’. FEBS Lett 583(11):1713–1720
Jjingo D, Conley AB, Yi SV, Lunyak VV, Jordan IK (2012) On the presence and role of human gene-body DNA methylation. Oncotarget 3(4):462–474
Jones PA (1999) The DNA methylation paradox. Trends Genet 15(1):34–37
Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13(7):484–492
Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3(4):253–266
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921
Ma X, Wang YW, Zhang MQ, Gazdar AF (2013) DNA methylation data analysis and its application to cancer research. Epigenomics 5(3):301–316
Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D’Souza C, Fouse SD et al (2010) Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466(7303):253–257
Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M et al (2016) Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun 24(7):10767
Pleyer L, Greil R (2015) Digging deep into “dirty” drugs-modulation of the methylation machinery. Drug Metab Rev 47(2):252–279
Rinke J, Schafer V, Schmidt M, Ziermann J, Kohlmann A, Hochhaus A et al (2013) Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA. Clin Chem 59(8):1238–1250
Schäfer V, Ernst J, Rinke J, Winkelmann N, Beck JF, Hochhaus A, Gruhn B, Ernst T (2016) EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol 142(7):1641–1650
Stresemann C, Bokelmann I, Mahlknecht U, Lyko F (2008) Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 7(9):2998–3005
Wang H, Hu H, Zhang Q, Yang Y, Li Y, Hu Y et al (2013) Dynamic transcriptomes of human myeloid leukemia cells. Genomics 102(4):250–256
Xie H, Wang M, Bonaldo Mde F, Smith C, Rajaram V, Goldman S et al (2009) High-throughput sequence-based epigenomic analysis of Alu repeats in human cerebellum. Nucleic Acids Res 37(13):4331–4340
Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP (2004) A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 32(3):e38
Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C et al (2013) Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One 8(5):e63812
Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J et al (2018) Ensembl 2018. Nucleic Acids Res 46(D1):D754–D761
Zheng Y, Joyce BT, Liu L, Zhang Z, Kibbe WA, Zhang W et al (2017) Prediction of genome-wide DNA methylation in repetitive elements. Nucleic Acids Res 45(15):8697–8711
Funding
This study was funded by the Interdisciplinary Center for Clinical Research (IZKF), Universitätsklinikum Jena, Germany.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Gawlitza, A.L., Speith, J., Rinke, J. et al. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes. J Cancer Res Clin Oncol 145, 2835–2843 (2019). https://doi.org/10.1007/s00432-019-03016-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-03016-9